Open Online KYC Account
NEED HELP? 1860 500 6543

HOURS : MON TO FRI (9:00 A.M. TO 6:00 P.M)

CaptionDateDescription
Krebs Biochemicals & Industries informs about reclassification of promoters 12-Jun-2019

Krebs Biochemicals & Industries has informed that pursuant to the application filed by the Company for reclassification of promoters to public category, the Company has received approval from BSE for the proposed classification on 11th June 2019. The Company further informed that approval from National Stock Exchange of India for the proposed reclassification was already received by the Company on 30th December 2016.

The above information is a part of company’s filings submitted to BSE.

Announcement Under Reg.30 Of SEBI (LODR) Regulations- Reclassification Of Promoters 12-Jun-2019
we herewith inform to the Exchange that pursuant to the application filed by the Company for reclassification of promoters to public category, the Company has received approval from BSE Limited for the proposed classification on 11th June 2019. We herewith also inform you that approval from National Stock Exchange of India Limited for the proposed reclassification was already received by the Company on 30th December 2016.
Appointment of Statutory Auditors 22-May-2019
inter alia, approved the following: a) Appointment of M/s Bhavani & Co., Chartered Accountants (Firm Registration No. 012139S) as Statutory Auditors of the Company subject to approval by the Shareholders of the Company in place of M/s Pavuluri & Co., who retires at the ensuing Annual General Meeting as per the provisions of Section 139 Companies Act, 2013. b) The amended code of code of practices and procedures of fair disclosure of Unpublished Price Sensitive Information under Regulation 8(1), Chapter IV of SEBI (Prohibition of Insider Trading) Regulations, 2015, which has been amended to incorporate additional clauses mandated by the SEBI (Prohibition of Insider Trading) Amendment Regulations, 2018.
Resignation of Statutory Auditor 22-May-2019
inter alia, approved the following: a) Appointment of M/s Bhavani & Co., Chartered Accountants (Firm Registration No. 012139S) as Statutory Auditors of the Company subject to approval by the Shareholders of the Company in place of M/s Pavuluri & Co., who retires at the ensuing Annual General Meeting as per the provisions of Section 139 Companies Act, 2013. b) The amended code of code of practices and procedures of fair disclosure of Unpublished Price Sensitive Information under Regulation 8(1), Chapter IV of SEBI (Prohibition of Insider Trading) Regulations, 2015, which has been amended to incorporate additional clauses mandated by the SEBI (Prohibition of Insider Trading) Amendment Regulations, 2018.
Krebs Biochemicals gets stop-production order from Andhra Pradesh Pollution Control Board 13-May-2019

Krebs Biochemicals and Industries has received stop-production order at its manufacturing unit located at Kothapalli (V), Kasimkota (M), Anakapalli, Vishakapatnam, Andhra Pradesh (Unit II) on May 10, 2019 from Andhra Pradesh Pollution Control Board citing ‘Non-compliance of Board directions and consent Order conditions.’

The company firmly believes in following the directions of the Board and is taking all necessary steps to comply with the observations cited by the Board in its order. The remedial measures are being undertaken and the company is confident that the issue will be resolved at the earliest.

Krebs Biochemicals & Industries is an India-based company. The Company operates in the pharma segment.

Intimation Under Reg.30 Of SEBI (LODR) Regulations, 2015 13-May-2019
we herewith intimate to the Exchange that the Company has received stop-production order at its manufacturing unit located at Kothapalli (V), Kasimkota (M), Anakapalli, Vishakapatnam, Andhra Pradesh (Unit II) on 10th May 2019 from Andhra Pradesh Pollution Control Board citing 'Non-compliance of Board directions and consent Order conditions.' The Company firmly believes in following the directions of the Board and is taking all necessary steps to comply with the observations cited by the Board in its order. The remedial measures are being undertaken and the Company is confident that the issue will be resolved at the earliest. This is for the information and records of the Exchange, Please.
Krebs Biochemicals & Industries informs about board meeting 23-Mar-2019

Krebs Biochemicals & Industries has informed that the meeting of the Board of Directors of the Company is scheduled on 25/03/2019, to consider and approve the allotment of shares pursuant to basis of allotment approved by the designated stock exchange.

The above information is a part of company’s filings submitted to BSE.


Krebs Biochemicals & Industries informs about board meeting 04-Feb-2019

Krebs Biochemicals & Industries has informed that the meeting of Board of Directors of the Company is scheduled to be held on Tuesday, 12th February 2019, to consider and approve the unaudited financial results along with the Limited Review Report for the quarter ended 31st December 2018; and any other matter with the permission of the Chair. Further, in connection to the above, trading window for dealing in shares of the Company will remain closed for the specified persons as defined in the Code from 5th February 2019 and shall re-open 48 hours after the publication of results to the public.

The above information is a part of company’s filings submitted to BSE.

Krebs Biochemicals & Industries informs about board meeting 07-Jan-2019

Krebs Biochemicals & Industries has informed that the meeting of Board of Directors of the company is scheduled to be held on Friday, 11th January 2019 to consider and approve the record date, pricing, final letter of offer and other allied matters pertaining to the proposed Rights Issue; and any other matter with the permission of the Chair. Further, in connection to the above, trading window for dealing in shares of the company will remain closed for the specified persons as defined in the code from 7th January, 2019 and shall re-open on 15th January 2019 after the publication of outcome to the public.

The above information is a part of company’s filings submitted to BSE.

Krebs Biochemicals & Industries informs about appointment of CFO 14-Sep-2018

In continuation to the outcome of the board meeting regarding appointment of S. Phani Srinath as Chief Financial Officer (CFO) of the company based on the recommendations of the Audit and Nomination and Remuneration Committees, vide the letter dated 10th September 2018, Krebs Biochemicals & Industries has informed about a brief profile of S. Phani Srinath as required under the Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

12

Copyright 2013 Inditrade Capital Ltd. All rights reserved.

Best Viewed in Resolution 1024 * 800 and Above